BUZZ-Enliven Therapeutics slips on $250 mln equity offering

Jefferies Financial
Enliven

Jefferies Financial

JEF

0.00

Enliven

ELVN

0.00

** Enliven Therapeutics' ELVN.O down 2.7% at $39.28 post-market after equity offering news

** Biopharma kicks off $250 mln offering comprising stock and pre-funded warrants

** Jefferies, Goldman Sachs, Morgan Stanley and Barclays joint bookrunners

** ELVN stock finished up 9.1% at $40.36 on Thurs after its leukemia drug, ELVN-001, showed encouraging early-stage results

** Boulder, Colorado-based firm has 60.9 mln shares outstanding for $2.5 bln market cap

** At close, stock up 162% YTD

** All 12 analysts rate the stock "strong buy" or "buy"; median PT $59.50, according to LSEG data


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.